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A B S T R A C T   
The large box jellyfish Chironex fleckeri is found in northern Australian waters. A sting from this cubozoan species 
can kill within minutes. From clinical and animal studies, symptoms comprise severe pain, welts, scarring, hy-
potension, vasospasms, cardiac irregularities and cardiac arrest. At present, there is no cure and opioids are used 
to manage pain. Antivenom is available but controversy exists over its effectiveness. Experimental and combi-
nation therapies performed in vitro and in vivo have shown varied efficacy. These inconsistent results are likely a 
consequence of the different methods used to extract venom. Recent omics analysis has shed light on the systems 
of C. fleckeri venom action, including new toxin classes that use pore formation, cell membrane collapse and ion 
channel modulation. This review covers what is known on C. fleckeri pathomechanisms and highlights current 
gaps in knowledge. A more complete understanding of the mechanisms of C. fleckeri venom-induced pathology 
may lead to novel treatments and possibly, the discovery of novel cell pathways, novel drug scaffolds and novel 
drug targets for human disease.   
1. Introduction 
Chironex fleckeri is a large box jellyfish commonly found in Australia 
waters, and suspected through out the Indo Pacific region (Fenner and 
Williamson, 1996; Gershwin et al., 2010; Lippmann et al., 2011; Tib-
balls, 2006). C. fleckeri has one of the most lethal and rapidly active 
venoms known (Bailey et al., 2005; Sizemore, 1987; Tibballs, 2006; 
Hartwick et al., 1980). C. fleckeri has caused 77 known fatal stings in the 
last century (Currie, 1994; Keesing et al., 2016) and with the greatest 
risk of envenoming occurring in northern Australian waters from 
October through May, though fatalities have been recorded in every 
month of the year except July (Currie, 2003). Nearly all envenomations 
occurred in shallow water beaches, 92% of stings occurred between 
October through June (Currie, 2005). 
Envenomation occurs at the epidermis, with jellyfish tentacles 
releasing hundreds of millions of nematocysts per sting (Fig. 1). Nem-
atocysts are biological syringes that eject small molecules, lipids, car-
bohydrates, proteins and small molecules into prey with harpoon-like 
protrusions that may be activated upon mechanical, osmotic, chemical 
and neuronal reception (Kass-Simon and Scappaticci, 2002). Clinical 
reports of non-fatal C. fleckeri envenomation have contributed to the 
understanding of systemic venom effects including severe pain, urticaria 
and scarring from nematocyst contact, hypotension, vasospasms, car-
diac irregularities and acute onset of cardiac arrest (Burnett et al., 1998; 
Cegolon et al., 2013; Nimorakiotakis and Winkel, 2003). There are no 
standard treatment options for C. fleckeri and envenomation given the 
pathomechanisms are unknown. A randomized controlled trial found no 
difference in efficacy between icepacks and hot water immersion in 
reducing pain (Isbister et al., 2017). Other treatments have been trialed 
including vinegar application, opioids and antivenom (Burnett et al., 
1990; Currie, 2005) (see Fig. 2). 
Given the potency and extremely rapid activity of C. fleckeri venom, 
it is interesting to note that many of these venom proteins have not been 
described in current gene or protein databases (Bailey et al., 2005; 
Brinkman et al., 2014, 2015; Burnett et al., 1996; Sizemore, 1987; 
Tibballs, 2006). C. fleckeri venom has pore-forming proteins and is 
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considered hemolytic, it may also have ion channel modulating char-
acteristics (Bailey et al., 2005; Burnett et al., 1996, 1998; Mustafa et al., 
1995). Mechanism of action studies on C. fleckeri venom have suggested 
ionophoric effects (Bailey et al., 2005; Freeman and Turner, 1969; 
Mustafa et al., 1995; Winter et al., 2007) and more research is needed. 
Given the potency and evolutionary distinctiveness of C. fleckeri venom, 
there is potential for venom-derived drug discovery and development 
(circulatory medicine etc.). Further study of this venom’s mode of action 
may lead to effective standard treatments. This review summarises what 
is known on the mechanism of C. fleckeri action and highlights knowl-
edge gaps. 
2. Animal pathophysiology following C. fleckeri envenomation 
Animal studies found that C. fleckeri venom had potent effects on the 
cardiovascular and pulmonary systems (Freeman and Turner, 1969; 
Ramasamy et al., 2005a,b; Tibballs et al., 1998). Effects included dra-
matic changes in arterial and venous pressure, heart rate, and abdominal 
respiratory physiology in anaesthetised rabbits and mice post exposure. 
C. fleckeri was extremely potent in extremely small volumes (0.1 mL of a 
5,000-fold dilution of tentacle extract) and was enough to kill a mouse 
within 2 min (Freeman and Turner, 1969). Rabbits challenged with 
C. fleckeri venom exhibited survival times between 1 and 6 min. The 
physiological effects in rabbits comprised: (i) bi-phasic blood pressure 
changes with resting arterial pressure rising from 115 mmHg to 140 
mmHg in 8 s; (ii) A plummet in arterial pressure to 225 mmHg followed 
a spike in 90 s; (iii) Apnea followed hypoxia; (iv) Respiratory failure and 
acute hypotension; (v) Bradycardia and a T-wave inversion; (vi) Arterial 
pressure failure and deteriorating heart rates (from 260 to 340 
beats/min to 100–150 beats/min) and; (vii) Finally, terminal respiratory 
failure (Freeman and Turner, 1969, 1971). These effects have been 
replicated in other studies (Burnett et al., 1998; Hughes et al., 2012; 
Tibballs et al., 1998). While the animal response to C. fleckeri venom has 
been well documented, clinical case reports are limited to describing 
basic symptoms such as welts on the epidermis or the cardiotoxic effects 
from fatalities (Currie, 2005). 
3. The effects of antivenom on C. fleckeri envenomation 
No one nationwide recommendation for first-aid can be made due to 
differences between jellyfish species. It was hoped that treatment with 
antivenom would prevent effects seen in severe envenomation by neu-
tralising causative toxins in the venom. The Commonwealth Serum 
Laboratories (CSL) first produced C. fleckeri antivenom in the 1970s 
using hyper-immunized sheep (Baxter and Marr, 1974; Currie and 
Jacups, 2005) and continue to produce antivenom. However, C. fleckeri 
antivenom efficacy has been called into question through data from 
animals and patients (Currie, 2003; Currie and Jacups, 2005; Endean 
and Sizemore, 1988; Konstantakopoulos et al., 2009; Ramasamy et al., 
2003; Winter et al., 2007, 2009). 
Studies using antivenom treatment post C. fleckeri venom challenge 
have produced varying results. In one study, mice administered anti-
venom after C. fleckeri venom challenge showed 7% survival (Endean 
and Sizemore, 1988). However, another study showed 59% survival 
after C. fleckeri venom challenge (Burnett et al., 1990). These findings 
were confirmed in a related study (Winter et al., 2009). Using rat aortic 
smooth muscle cell line, C. fleckeri antivenom treatment showed no 
neutralisation (Konstantakopoulos et al., 2009). Interestingly, a dose 
study reported that the high amounts of antivenom did not improve 
protection in piglets (Tibballs et al., 1998) suggesting a concentration 
limit for efficacy. These results were confirmed in another study which 
showed the antivenom was effective within a limited dose range 
(Andreosso et al., 2014; Bloom et al., 1999). 
Due to the underwhelming effects of antivenom in animal models, 
researchers next examined antivenom prophylactically. Prophylactic 
use of antivenom prolonged the survival time of mice by 5-fold (Endean 
and Sizemore, 1988). A separate study showed that while prophylactic 
administration of antivenom did not have any effect on blood pressure 
after envenomation, the antivenom did prevent cardiovascular collapse 
in 40% of test animals (Ramasamy et al., 2004). In contrast, another 
prophylactic study reported improved arterial pressure post low dose 
administration (Hughes et al., 2012; Ramasamy et al., 2004; Winter 
et al., 2007). In a follow up study, antivenom given 15 min before venom 
delivery did not prevent cardiovascular collapse and a very high dose 
was unable to attenuate venom effects (Winter et al., 2009). In addition, 
antivenom administered with magnesium sulfate could prevent 
Fig. 1. C. fleckeri tentacle nematocysts firing. C. fleckeri nematocyst spikes 
imaged in vitro using a high speed phantom VEO camera https://biopixel.tv/. 
Fig. 2. Clinical symptoms and mechanisms underlying C. fleckeri envenomation. Flow chart includes known physiological responses to C. fleckeri envenom-
ation in case studies or in vivo and highlights unknown mechanisms of action associated with these responses. 
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cardiovascular collapse (Ramasamy et al., 2004). Collectively, prophy-
lactic administration of antivenom shows varying effects and is 
impractical. 
Another methodology was to combine C. fleckeri venom with anti-
venom and administer the mixture. This improved cell survival in vitro 
and improved animal survival (Andreosso et al., 2014; Kon-
stantakopoulos et al., 2009; Tibballs et al., 1998; Winter et al., 2009). In 
a related study, CSL antibodies were compared with polyclonal rabbit 
antibodies raised against nematocyst-derived venom (Winter et al., 
2009). Neither were effective therapeutically. Again, mixing C. fleckeri 
venom with antivenom is an impractical solution. 
There is currently no consensus on how much antivenom is required 
to be effective. From animal data, effective antivenom amounts would 
be 3–4 fold higher than is suggested for humans (Andreosso et al., 2014; 
Endean and Sizemore, 1988). Two studies have reported risk of adverse 
reactions at low antivenom doses (Sutherland, 1977; Williamson et al., 
1980) and a clinical case study in Australia reported that only 5% of 
patients received antivenom for C. fleckeri envenomation (Currie and 
Jacups, 2005). In addition to these data, there has been 4 fatalities even 
after the use of antivenom (Currie and Jacups, 2005). 
4. Experimental and combination therapies for C. fleckeri 
envenomation 
The effects of C. fleckeri venom on small mammalian physiology have 
been examined with various experimental therapeutics (Bloom et al., 
1999; Burnett, 1989; Burnett et al., 1998; Freeman and Turner, 1969; 
Isbister et al., 2004a,b; Ramasamy et al., 2005a, b; Tibballs, 2006). Due 
to the effects on the cardiovascular and pulmonary systems, one study 
looked at the combined effect of antivenom with Verapamil. Verapamil 
is a calcium channel blocker which has been shown to relax the muscles 
of the heart and is used to treat high blood pressure, angina, and cardiac 
arrhythmias (Burnett et al., 1990; Guyton, 2011). Post injection with 
C. fleckeri venom, all untreated mice died within 7.5 min of venom 
administration. Here, 59% of the animals administered antivenom died 
within 3 min, 68% of the animals administered Verapamil died within 
24 min, and 26% of mice given a mixture of antivenom and Verapamil 
died within 34 min (Burnett et al., 1990). Thus, Verapamil exhibited 
prolonged survival times. A related study attempted a rescue experiment 
post envenomation using a combination of antivenom and Verapamil 
(Bloom et al., 1999). This treatment nearly doubled the survival time. 
However, addition of verapamil to a higher dose of antivenom did 
not increase survival time. Antivenom alone was shown ineffective. 
These findings were confirmed in a similar study (Winter et al., 2009). 
Additional studies using Verapamil have also shown inconsistent 
results prophylactically and therapeutically (Burnett et al., 1990; Isbis-
ter et al., 2004a; Tibballs et al., 1998). It was additionally noted that 
Verapamil may cause hypotension, vasodilation and have adverse 
inotropic effects (Tibballs et al., 1998). However, another calcium 
channel blocker, Felodipine, was able to block the C. fleckeri venom 
effects in vitro (further detailed in section 5) (Winter et al., 2007). 
Collectively, the results of C. fleckeri venom treatment have been 
inconsistent both in vitro and in vivo. 
5. Consistencies and variabilities in animal testing 
Overall, the above animal studies consistently found C. fleckeri 
venom caused the following effects in mice, rats, rabbits, and piglets: (i) 
bi-phasic pressor responses with extreme hypertension followed by hy-
potension and; (ii) cardiovascular collapse and cardiotoxicity charac-
terised by electrophysiology dysfunction with survival times as short as 
1–2 min. One aspect that makes comparing results between studies 
difficult is varying concentrations of venom used in testing. Importantly, 
historical animal studies did not report venom profiles which may 
contribute to the variability between results. Two aspects that 
contribute to the venom profile are, collection site and ontogenetic 
variations. For instance, C. fleckeri venom from Weipa, Australia was 
found to be more lethal compared with venom taken from Mission 
Beach, Australia, a location nine hundred kilometres south (Brinkman 
et al., 2014; Winter et al., 2009). The size of the jellyfish is also relevant. 
Extremely potent cardiotoxic venom has been observed in large 
C. fleckeri samples (Brinkman et al., 2014; McClounan and Seymour, 
2012). In future, it would be informative to examine C. fleckeri speci-
mens from multiple regions across Australian waters. 
The only common finding from these above experiments is the rapid 
action of the venom. Treatments either increased survival times (Bloom 
et al., 1999) or not (Burnett et al., 1990). These inconsistencies may 
arise from several factors that could be attributed to venom geo-
graphy/profile/preparation rather than variation in methodology. The 
venom profile in each of these studies was not documented and likely 
would have varied due to different venom extraction techniques. For 
example, an in vitro and an in vivo study showed inconsistent results of 
Verapamil (Bloom et al., 1999). Another calcium channel blocker, 
Felodipine (T-type calcium channel blocker), significantly reduced the 
contractile force in isolated rat aorta (Winter et al., 2007). The most 
effective treatments shown thus far are all based on ionophoric mech-
anisms (Bailey et al., 2005; Mustafa et al., 1995; Freeman and Turner, 
1969). Non-specific voltage gated calcium channels may be involved 
rather than L-type voltage gated calcium channels. Immunisation has 
been considered as a treatment for C. fleckeri venom (Alam and Ashraf, 
2013). Whether this is practical or cost effective is unlikely. 
6. The divergent methods of C. fleckeri venom extraction 
Isolating pure venom from jellyfish tentacles has presented a sig-
nificant challenge for researchers. The capsular organelles that deliver 
the venom have highly specialised anatomy and there are several classes 
of nematocysts (Gershwin, 2006). Researchers have attempted 
numerous isolation techniques. The first venom extraction method was 
from milked venom (Barnes, 1967). While this collection technique was 
aimed to imitate natural envenomation, the authors reported the 
resulting material was contaminated with amniotic proteins and resul-
ted in low antivenom yields from immunized animals. 
The first mechanical activation of nematocysts involved mortar and 
pestle grinding in ice and filtered seawater, which resulted in low venom 
yields (Endean et al., 1969). Subsequent mechanical disruption of 
nematocysts involved whole tentacle homogenisation that was centri-
fuged at low temperatures termed “homogenate venom extraction” 
(Freeman and Turner, 1969). Another technique was beachside sepa-
ration of tentacle material from nematocysts. This was performed by 
refrigerating tentacles in sea water for 1–4 days. Nematocysts were 
separated from debris in solution with a fine sieve and preserved in al-
iquots for freezing (Bloom et al., 1998). Other mechanical extraction 
techniques separated the nematocysts from the tentacle and then acti-
vated the nematocysts. This technique was termed “crude venom 
extraction”. Yet another example was the use of sonar or high frequency 
sound to rupture the nematocyst capsular organelles (Burnett et al., 
1998; Mustafa et al., 1995). Many early mechanical disruption tech-
niques involved grinding nematocysts for long periods which exposed 
the venom to protracted raised temperatures (Endean et al., 1969). This 
lead to the discovery of the thermolabile nature of C. fleckeri venom 
(Bloom et al., 1998; Burnett et al., 1998; Carrette and Seymour, 2004; 
Endean et al., 1969). 
Researchers have also explored chemical extraction. One method, 
soaked tentacles in ethanol for 24hr to activate nematocysts (Jouiaei 
et al., 2015). This extraction method allowed venom collection in one 
step and revealed novel proteins. However, it is likely that exposing the 
venom to strong alcohol would lead to protein degradation. Since heat 
and chemical extraction techniques rendered venom components to 
degradation, a cold mechanical method was developed (Carrette and 
Seymour, 2004). This protocol involved soaking tentacles in sea water 
for five days which caused nematocysts to detach from the tentacles. A 
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strainer was then used to separate the nematocysts from the soaking 
solution. The strained solution was centrifuged and the nematocyst 
pellet was placed into a mini-glass-bead beater. The mechanical agita-
tion of the nematocysts was repeated to allow for maximum venom 
yield. The process took place in a cold room to ensure nematocysts 
remained temperature stable throughout. The venom was then pipetted 
off and passed through a micro filter before experimental use. Another 
method used both chemical and ethanol extraction to obtain purified 
porin fractions of the C. fleckeri venom (Yanagihara and Shohet, 2012). 
The study used this technique in vitro and in vivo and concluded that a 
pore forming mechanism must be the foremost mechanism of action of 
C. fleckeri whole venom. Hydrolysis was not observed and this extraction 
method may not reflect the results observed in the natural setting given 
it alters venom compounds. 
Another study aimed to investigate the mechanism responsible for 
the hallmark bi-phasic blood pressure response to C. fleckeri envenom-
ation from two different venom samples from separate extraction tech-
niques (Ramasamy et al., 2005b). They showed that a pure sample 
extracted from nematocysts versus tentacle extact had pharmacologi-
cally distinct cardiovascular effects in rodents. 
These differing extraction methods have shown that C. fleckeri 
venom activity is sensitive to changes in heat, freezing, thawing and 
blunt-force grinding. Many methods effect venom composition and/or 
generate low yields (Bloom et al., 1999; Carrette and Seymour, 2004; 
Endean et al., 1969; Othman and Burnett, 1990; Ramasamy et al., 
2005a,b; Olson et al., 1984). Thus, a significant barrier to progress is the 
lack of standardisation of venom extraction. A standardised method for 
venom extraction that has minimal-to-no impact on venom composition 
will allow for more robust and replicable experiments between research 
sites. 
7. The ‘omics’ of C. fleckeri venom 
The transcriptomics and proteomics of C. fleckeri venom is complex. 
Studies using SDS-page gel have identified two proteins of interest, 
CfTX-1 and CfTX-2 (Brinkman and Burnell, 2007). These proteins are 
hemolytic or pore-forming toxins that have close homology with three 
other box jellyfish species, Chiropsalmus quadrigatus, Carybdea rastoni 
and Alatina alata which are also known to show hemolytic properties in 
their venom (Brinkman and Burnell, 2007). The conserved amino acid 
region (TSR1) found in C. fleckeri and other cubozoan toxins, may be 
responsible for the pore forming action of these toxins (Brinkman and 
Burnell, 2007; Daly et al., 2014). Fractionation of C. fleckeri venom using 
size exclusion and cation exchange chromatography revealed further 
complexity through the identification of three additional toxins, CfTX-A, 
CfTX-B and CfTX-Bt. Here, CfTX-2 was referred to as Type I toxin and 
CfTX-1and CfTX-2 were referred to as Type II toxins (Brinkman et al., 
2014). These two toxin types were determined using bioinformatics 
based on phylogenetic similarities. Type II toxins showed close struc-
tural homology to a 3d-Cry toxin, which are known to induce cell lysis 
and death through pore forming action (Brinkman et al., 2014). 
Finally, a recent transcriptomic and proteomic study of C. fleckeri 
venom revealed ~20,000 predicted proteins and over 150 potential 
toxins by transcriptomics. Over 250 proteins were revealed by LC MS/ 
MS with the most abundant proteins having little-to-no blast homology 
to known animal or plant proteins (Brinkman et al., 2015). 
8. The varying mechanisms of action from C. fleckeri venom 
fractions 
One of the first studies to provide insight into the molecular mech-
anism of C. fleckeri envenomation was a study on the effect on cardiac 
transmembrane potentials (Freeman, 1974). Dissections of rabbit and 
guinea pig hearts were perfused with two fractions of C. fleckeri venom 
obtained via size exclusion chromatography and were termed car-
diotoxin and haemolytic/cardio toxin. The cardiotoxin reduced atrial 
action potential spike height, maximal diastolic potential and maximal 
rate of rise of action potential. Effects of the cardiotoxin on right atrial 
preparations showed sinoatrial (SA) and atrioventricular (AV) node 
depression, thus producing an action potential. That would undershoot 
normal contestations. It was suggested that these changes were the ef-
fects of increased sodium permeability in the cell. Indeed, it had been 
previously shown that the inhibition of depolarization of Purkinje fibers 
with a sodium ion channel blocker, Tetrodotoxin (TTX), would restore 
cardiac action potentials (Hogan and Albuquerque, 1971). TTX was 
trialed to attenuate the effects of C. fleckeri venom fractions with minor 
effects (Freeman, 1974). Interestingly, washing the tissue was found to 
reverse the cardiotoxic effects, but the cardiotoxin and haemolytic toxin 
fraction combination was non-reversible. Thus, it was concluded that 
venom fractions contained distinct proteins, and that the two fractions 
exerted effects by different mechanisms. A more recent study showed 
similar findings. Chironex fleckeri venom was fractionated using fast 
protein liquid chromatography to isolate the cardiotoxic proteins of the 
venom which revealed new subfractions from CfTX-1 or CfTX-2 
(Chaousis et al., 2014). Three subfractions were identified comprising 
CTF-α, CTF-β, and CTF-γ. A cell metabolism assay was used to monitor 
the effects of the fractions on human skeletal muscle cell and cardiac 
myocyte metabolism. This study found that CTF-α and, CTF-β were 
cytotoxic to cardiac myocytes and not skeletal muscle cells. CTF-α and 
CTF-β were observed to have a synergistic effect causing faster and 
permanent cell detachment and death than either toxin fraction alone. 
The third fraction, CTF-γ, was toxic to muscle cells but not car-
diomyocytes. Since the study observed cellular recovery after 3 h, they 
concluded their findings did not align completely with a pore forming 
mechanism of action (Chaousis et al., 2014). 
9. Ionophoric action as a potential mechanism of action for 
C. fleckeri venom activity 
Interest in the cardiotoxic molecular mechanism of C. fleckeri venom 
led to an in vitro study on the contractile force of isolated cardiac cells 
and membrane potentials (Mustafa et al., 1995). The administration of 
C. fleckeri whole venom led to large increased intracellular calcium 
influx which caused spontaneous contractions, a decrease in developed 
force and an increase in resting force. Since calcium is vital for atrial 
contraction, calcium ion channels were thought to be responsible for this 
intense cardiac response. The response of papillary muscle contractility 
was not attenuated with the L-type calcium channel blockers Nifedipine, 
TTX or the sarcoplasmic reticulum inhibitor (Ryanodine). The isolated 
myocytes increased intracellular sodium concentrations preceding a 
large calcium influx. The study then preincubated papillary muscles 
with Ni2þ to block C. fleckeri venom effects. Ni2þ significantly attenu-
ated the effect of C. fleckeri venom. This result led to the hypothesis that 
C. fleckeri venom could be acting through the activation of an Naþ/Ca2þ
exchanger. The study concluded that it was unlikely that the increase in 
Ca2þ was due to nonspecific membrane damage given the effects 
appeared so quickly after venom exposure. 
An early study of C. fleckeri venom used anaesthetised Wistar rats 
(Rattus norvegicus) to monitor arterial and venous pressure, heart rate 
and abdominal respiratory movements (Freeman and Turner, 1969). 
The cause of death was from cardiotoxicity which was supported by 
interference with repolarization and conduction of atrial action poten-
tials. It was reported that the toxin was haemolytic. Elevated plasma 
potassium was not consistently high enough to be related to the cardiac 
irregularities (Southcott and Kingston, 1959). The study concluded that 
the venom likely alters membrane permeability (Freeman and Turner, 
1969). A more recent study used isolated rat aorta to measure the 
vascular effects of C. fleckeri venom (Winter et al., 2007). A venom 
titration produced a concentration independent sustained contraction of 
the endothelium-denuded aortic tissue. This study attempted to block 
the effects of the venom with Felodipine, which significantly reduced 
coronary flow velocity. Due to the positive effects of Felodipine 
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treatment in vitro, the study speculated an ionophoric mechanism of 
action may be responsible for the effects of C. fleckeri venom. 
Further studies on the molecular mechanism of C. fleckeri venom 
sought to confirm the increase of cytosolic calcium in myocytes as a 
cause for cardiotoxicity (Bailey et al., 2005). Here, cardiac ventricular 
myocytes were isolated and treated with a Indo-1 Ca2þ indicator dye 
before the addition of C. fleckeri venom. Cells pre-incubated with either 
lanthanum chloride or Verapamil prior were then exposed to C. fleckeri 
venom (Bailey et al., 2005). Chironex fleckeri venom caused an increase 
in free cytosolic Ca2þ. C. fleckeri venom applied to myocytes pre-
incubated with Verapamil resulted in an increase in free cytosolic Ca2þ. 
C. fleckeri venom applied to preincubated myocytes with lanthanum 
caused an increase in free cytosolic Ca2þ. Thus, the study showed that 
C. fleckeri venom did cause an increase in cytosolic calcium levels. To 
further investigate the source responsible for increased cytosolic cal-
cium ions (i.e. intracellular or extracellular stores of calcium), manga-
nese (Mn2þ) Fura-2 quench reactions were performed. Mn2þ passes 
through the cell membrane using the same ion channels as Ca2þ. The 
Mn2þ experiment determined that there was a notable permeability of 
Ca2þ into the myocytes under resting conditions. Venom dramatically 
increased the rate of extracellular Mn2þ influx into the cell. Thus, the 
increase in cytosolic Ca2þ is likely originating from the extracellular 
fluid via ion channels (Bailey et al., 2005). This was an important finding 
as it was previously thought the sarcoplasmic reticulum was the source 
of excess cytosolic calcium (Mustafa et al., 1995). Overall, several 
studies have proposed that different fractions of C. fleckeri venom have 
different mechanisms of action (Freeman, 1974; Chaousis et al., 2014; 
Ramasamy et al., 2005b). While the established mechanism for 
C. fleckeri venom pathology is proposed to be ionophoric-based (Bailey 
et al., 2005; Freeman and Turner, 1969; Mustafa et al., 1995; Winter 
et al., 2007), the exact voltage gated ion channels involved are un-
known. Further research is required to confirm that calcium enters from 
the cell versus the extra cellular space (Bailey et al., 2005). 
Three studies have tested three compounds (Nifedepine, Verapamil 
and Felodipine) all which were voltage gated calcium channel blockers. 
Only one compound (Nifedepine) was unable to attenuate C. fleckeri 
venom response (Mustafa et al., 1995). Nifedepine inhibits L-type 
channels but does block other members of the calcium ion channels 
families. Of these calcium channel blockers, only Verapamil has been 
tested in human envenomation (Currie, 2005). Felodipine has been 
tested in vitro and was shown to have some efficacy (Winter et al., 2007). 
Finally, a very recent study also suggests that C. fleckeri venom likely 
has several more mechanisms of action (Lau et al., 2019). Using a 
genome-scale CRISPR knockout (GeCKO) screen, plasma membrane 
lipids were identified as key components in the cytotoxicity mechanism. 
Through the use of methyl-β-cyclodextrin or 2-hydrox-
ypropyl-β-cyclodextrins, which deplete cholesterol from the cell mem-
brane, researchers were able to attenuate the venom response in human 
cell lines. Treatment with cyclodextrins attenuated both necrosis and 
pain when administered after venom in animal models. 
10. Future directions and conclusion 
Animal studies have laid the ground work for understanding the 
mechanism of action of C. fleckeri venom. Across the literature, treat-
ment and survival are highly variable in animal experiments. Improve-
ments could be made in the future by adopting a standardisation of 
venom preparation as previous described (Carrette et al., 2002). This 
would be key in facilitating more robust conclusions across different 
sites. Future studies should also report the venom profile by SDS, HPLC, 
FPLC or LC/MS/MS for quality control. Additionally, since cardiotox-
icity is well characterised by ion channel disruption, monitoring the 
effects of the venom on the ion channels of primary afferent (pain 
sensing) neurons may be a logical place for future studies to begin 
characterizing the pain aspect of envenomation. Another consideration 
for future studies would be to use C. fleckeri venom to map pain 
pathways, as severe pain is a hallmark clinical symptom. 
As described above, it has been reported that C. fleckeri antivenom is 
ineffective in vivo. Additionally, it remains unclear if C. fleckeri anti-
venom can mitigate clinical symptoms. A number of studies have found 
that the antivenom may opsonize the venom if premixed. However, 
these approaches are not practical. The venom extraction studies agreed 
that C. fleckeri venom was susceptible to heat and (Carrette and Sey-
mour, 2004; Olson et al., 1984). The varying conditions in venom 
extraction can cause active proteins to denature and/or aggregate 
dramatically altering the venoms’ potency (Endean et al., 1969; Othman 
and Burnett, 1990). Future studies should use the most non-invasive 
extraction technique that minimizes venom exposure to temperature 
changes and severe mechanical disruption. The cold mechanical 
extraction technique meets these requirements. 
Additional omics work is needed. A full genome C. fleckeri sequence 
analysis has yet to be performed, nor detailed analysis of PTMs, small 
molecules, lipids or polysaccharides. Finally, marine phyla are highly 
underrepresented in current protein and nucleotide databases. More 
information is needed given the species diversity in Earth’s oceans. 
To better the understand mechanism of action of C. fleckeri venom, 
further ion channel physiology experiments are required. Future 
research should utilize new high-throughput techniques (Inserra et al., 
2017; Vetter et al., 2012). In vitro treatments that attenuate C. fleckeri 
venom activity have been based on the assumption of ionophoric ac-
tivity. Since calcium ion conductance from the extracellular fluid has 
been confirmed to occur upon C. fleckeri venom exposure, future 
research should investigate the involvement of the other voltage gated 
calcium ion channels (Freeman, 1974). 
In conclusion, the studies have contributed invaluable information 
on the mechanism of action of C. fleckeri venom and has revealed areas 
where future work is needed. Animal experiments have been crucial in 
understanding the mammalian physiological response. Antivenom 
studies have given key insights to the rapid kinetics of C. fleckeri venom 
and have highlighted that more work is needed to improve efficacy. 
Venom extraction studies have helped emphasise data inconsistencies 
across sites and have highlighted the need for a standardised protocol for 
venom extraction and profiling. Omics and CRISPR studies are begin-
ning to allow a very comprehensive look on mechanism of action. 
Collectively, these studies will assist in the development of novel 
treatments for C. fleckeri envenomation and potentially, the discovery of 
novel cell pathways and scaffolds for next generation pharmaceuticals 
(Jimenez et al., 2018). 
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